^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

YL-17231

i
Other names: YL-17231, TEB-17231, YL17231
Company:
Shanghai YingLi Pharma
Drug class:
KRAS G12C inhibitor, KRAS G12D inhibitor, pan-KRAS inhibitor
1year
New P1 trial • Metastases
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
KRAS mutation • NRAS mutation • HRAS mutation
|
YL-17231
1year
A Study of YL-17231 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=80, Recruiting, Shanghai YingLi Pharmaceutical Co. Ltd.
New P1 trial • Metastases
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability)
|
MSI-H/dMMR • KRAS wild-type • RAS wild-type
|
YL-17231